Sector Gamma AS Purchases 2,000 Shares of Humana Inc. (NYSE:HUM)

Sector Gamma AS lifted its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 16.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,000 shares of the insurance provider's stock after purchasing an additional 2,000 shares during the period. Humana accounts for about 1.2% of Sector Gamma AS's portfolio, making the stock its 24th biggest position. Sector Gamma AS's holdings in Humana were worth $3,552,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. FPC Investment Advisory Inc. bought a new stake in shares of Humana in the 4th quarter valued at $27,000. Centricity Wealth Management LLC bought a new stake in Humana in the fourth quarter valued at $30,000. LFA Lugano Financial Advisors SA boosted its position in shares of Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after purchasing an additional 45 shares in the last quarter. OFI Invest Asset Management bought a new position in shares of Humana during the 4th quarter worth about $33,000. Finally, Atwood & Palmer Inc. grew its stake in shares of Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after buying an additional 60 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Stock Performance

Shares of NYSE HUM traded up $1.79 during trading on Tuesday, reaching $273.51. 1,392,567 shares of the stock traded hands, compared to its average volume of 1,717,036. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market capitalization of $33.01 billion, a P/E ratio of 27.49, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a 50-day moving average of $270.83 and a 200-day moving average of $275.00.

Remove Ads

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.29%. Humana's dividend payout ratio is 35.58%.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.37% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Piper Sandler increased their price target on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a report on Wednesday, January 15th. StockNews.com downgraded shares of Humana from a "buy" rating to a "hold" rating in a research report on Tuesday, March 18th. Barclays upped their price objective on shares of Humana from $255.00 to $270.00 and gave the stock an "equal weight" rating in a report on Thursday, February 13th. Truist Financial lifted their price objective on shares of Humana from $260.00 to $290.00 and gave the company a "hold" rating in a report on Monday, January 6th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $290.00 target price on shares of Humana in a research report on Wednesday, February 12th. Eighteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Humana presently has an average rating of "Hold" and a consensus target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.